• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Evox Therapeutics completes $95.4M Series C

February 18, 2021 By Sean Whooley

Evox TherapeuticsEvox Therapeutics announced today that it raised $95.4 million (£69.2 million) in a Series C financing round.

Oxford, England-based Evox’s financing was significantly oversubscribed with high demand from both existing and new investors, according to a news release.

Redmile Group led the financing while being joined by new investors OrbiMed and Invus. OrbiMed partner Chau Khuong also joined Evox’s board of directors.

All existing Series B investors, including Redmile, reinvested in the Series C, including Oxford Sciences Innovation, GV (formerly Google Ventures) and Cowen Healthcare Investments.

In addition to all of the investors, Eli Lilly converted a $10 million convertible note, formed as part of a 2020 collaboration between the two companies, into equity to contribute to the round.

Evox said the proceeds collected in the round will be used to support the advancement of its exosome-based therapeutics pipeline, including the development of its DeliverEX exosome drug platform.

The company works to harness and engineer the delivery capabilities of extracellular vesicles, known as exosomes, to develop new therapeutics. The proprietary DeliverEX technology modifies exosomes using molecular engineering, drug loading and targeting strategies to facilitate targeted drug delivery to organs of interest.

“We are delighted with the support received in this Series C financing from both our existing investors and our new investors,” Evox CEO Dr. Antonin de Fougerolles said in the release. “The level of interest in this financing round is testament to the progress we have made over the last few years. Since our Series B round in 2018, we have continued to develop our DeliverEX platform, advance our pipeline of exosome therapeutics, expand our intellectual property portfolio, build our R&D capabilities and bolster our management team.

“We have also signed significant partnership deals with Eli Lilly and Takeda, two of the world’s leading pharma companies. We welcome Chau Khuong to our Board and look forward to his contributions as Evox enters its next phase of growth.”

Filed Under: Business/Financial News, Featured, Funding Roundup, Pharmaceuticals, Research & Development Tagged With: Eli Lilly & Co., evoxtherapeutics, Takeda Pharmaceutical Co

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS